Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never became a big part of the genetic testing company’s business, but it is getting a new life by joining Regeneron Genetics Center, a Regeneron subsidiary that analyzes genetic data for drug R&D.
The post 23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron’s Gene-Based Drug R&D Efforts appeared first on MedCity News.
